362 related articles for article (PubMed ID: 33667843)
1. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.
Gaston TE; Ampah SB; Martina Bebin E; Grayson LP; Cutter GR; Hernando K; Szaflarski JP;
Epilepsy Behav; 2021 Apr; 117():107862. PubMed ID: 33667843
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.
Szaflarski JP; Bebin EM; Cutter G; DeWolfe J; Dure LS; Gaston TE; Kankirawatana P; Liu Y; Singh R; Standaert DG; Thomas AE; Ver Hoef LW;
Epilepsy Behav; 2018 Oct; 87():131-136. PubMed ID: 30100226
[TBL] [Abstract][Full Text] [Related]
3. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program.
Park YD; Linder DF; Pope J; Flamini JR; Moretz K; Diamond MP; Long SA
Epilepsy Behav; 2020 Nov; 112():107474. PubMed ID: 33181893
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy.
Gaston TE; Szaflarski M; Hansen B; Bebin EM; Szaflarski JP;
Epilepsy Behav; 2019 Jun; 95():10-17. PubMed ID: 31003195
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.
Sands TT; Rahdari S; Oldham MS; Caminha Nunes E; Tilton N; Cilio MR
CNS Drugs; 2019 Jan; 33(1):47-60. PubMed ID: 30460546
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.
Szaflarski JP; Bebin EM; Comi AM; Patel AD; Joshi C; Checketts D; Beal JC; Laux LC; De Boer LM; Wong MH; Lopez M; Devinsky O; Lyons PD; Zentil PP; Wechsler R;
Epilepsia; 2018 Aug; 59(8):1540-1548. PubMed ID: 29998598
[TBL] [Abstract][Full Text] [Related]
9. Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol.
Szaflarski JP; Hernando K; Bebin EM; Gaston TE; Grayson LE; Ampah SB; Moreadith R
Epilepsy Behav; 2019 Jun; 95():131-136. PubMed ID: 31048098
[TBL] [Abstract][Full Text] [Related]
10. Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy.
Martin RC; Gaston TE; Thompson M; Ampah SB; Cutter G; Bebin EM; Szaflarski JP
Epilepsy Behav; 2019 Aug; 97():105-110. PubMed ID: 31220785
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsy.
Nenert R; Allendorfer JB; Bebin EM; Gaston TE; Grayson LE; Houston JT; Szaflarski JP
Epilepsy Behav; 2020 Nov; 112():107297. PubMed ID: 32745959
[TBL] [Abstract][Full Text] [Related]
12. Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.
Gaston TE; Bebin EM; Cutter GR; Ampah SB; Liu Y; Grayson LP; Szaflarski JP;
Epilepsy Behav; 2019 Sep; 98(Pt A):201-206. PubMed ID: 31382177
[TBL] [Abstract][Full Text] [Related]
13. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.
Patel S; Grinspoon R; Fleming B; Skirvin LA; Wade C; Wolper E; Bruno PL; Thiele EA
Epilepsia; 2021 Jul; 62(7):1594-1603. PubMed ID: 34050682
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam.
Savage TE; Sourbron J; Bruno PL; Skirvin LA; Wolper ES; Anagnos CJ; Thiele EA
Epilepsy Res; 2020 Feb; 160():106263. PubMed ID: 31923763
[TBL] [Abstract][Full Text] [Related]
15. Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy.
Pietrafusa N; Ferretti A; Trivisano M; de Palma L; Calabrese C; Carfì Pavia G; Tondo I; Cappelletti S; Vigevano F; Specchio N
Paediatr Drugs; 2019 Aug; 21(4):283-290. PubMed ID: 31179531
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: Four-year results from the expanded access program.
Szaflarski JP; Devinsky O; Lopez M; Park YD; Zentil PP; Patel AD; Thiele EA; Wechsler RT; Checketts D; Sahebkar F
Epilepsia; 2023 Mar; 64(3):619-629. PubMed ID: 36537757
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.
Hess EJ; Moody KA; Geffrey AL; Pollack SF; Skirvin LA; Bruno PL; Paolini JL; Thiele EA
Epilepsia; 2016 Oct; 57(10):1617-1624. PubMed ID: 27696387
[TBL] [Abstract][Full Text] [Related]
19. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy.
Villanueva V; García-Ron A; Smeyers P; Arias E; Soto V; García-Peñas JJ; González-Alguacil E; Sayas D; Serrano-Castro P; Garces M; Hampel K; Tomás M; Lara J; de Toledo M; Barceló I; Aledo-Serrano A; Gil-Nagel A; Iacampo L; Falip M; Saiz-Diaz RA; Gómez-Ibañez A; Sopelana D; Sanchez-Larsen A; López-González FJ
Epilepsy Behav; 2022 Dec; 137(Pt A):108958. PubMed ID: 36327646
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy: A Randomized Clinical Trial.
O'Brien TJ; Berkovic SF; French JA; Messenheimer JA; Sebree TB; Bonn-Miller MO; Gutterman DL;
JAMA Netw Open; 2022 Jul; 5(7):e2220189. PubMed ID: 35802375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
